Touchlight and LenioBio collaborate to accelerate development of protein therapeutics for pandemic response Published: 2 July 2024 Touchlight to participate in LenioBio’s recently announced grant from CEPI 02 July, HAMPTON,…
TOM MERRITT, PH.D. Traditional methods for the production of adeno-associated viral (AAV) vectors — crucial components in gene therapies — rely on plasmid DNA (pDNA), which can pose safety concerns…
Touchlight Genetics and the National Physical Laboratory (NPL) awarded grant to develop novel gene-length single-stranded genome editing template. Published: 9 May 2024 Touchlight Genetics, in partnership with the National Physical…
Touchlight awarded grant extension to further develop DNA-enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory Published: 26 April 2024 Touchlight, a biotechnology CDMO…
University of Liverpool to use Touchlight’s rapid enzymatic dbDNA in fully personalised neoantigen cancer vaccine clinical study Published: 4 April 2024 The UK’s Medical Research Council is funding a 10-patient…
Touchlight awarded tender to supply enzymatic dbDNA to CPI’s RNA Centre of Excellence Published: 28 March 2024 Touchlight, an innovation-driven CDMO enabling the development of genetic medicines with its doggybone…
Elena Stoyanova, Hyatt Balke-Want, Marianna Romito, Debra Barberini In this virtual seminar, cell engineering scientists from Stanford University, Touchlight Genetics, and MaxCyte share promising advances in non-viral gene therapy. Join…
Touchlight’s enzymatic doggybone DNA used in the manufacture of Versameb’s VMB-100 for first-in-human clinical study Published: 21 November 2023 Based on prior manufacturing agreement that encompasses usage of Touchlight’s doggybone…
Curia expands biologics capabilities with access to Touchlight’s doggybone DNA Published: 24 July 2023 Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone…